
Trifarotene

Trifarotene, sold under the brand name Aklief, is a medication for the topical treatment of facial and truncal acne vulgaris in those nine years of age and older. It is a retinoid; more specifically, it is a fourth generation selective retinoic acid receptor (RAR)-γ agonist.
It was approved for medical use in the United States in 2019, and is approved in the European Union for the treatment of acne. Trifarotene was granted orphan drug designation for the treatment of congenital ichthyosis by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).